HER2 Gene Mutation Recruiting Phase 1 Trials for Trastuzumab emtansine (DB05773)

IndicationStatusPhase
DBCOND0081068 (HER2 Gene Mutation)Recruiting1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT05650879ELVN-002 in HER2 Mutant Non-Small Cell Lung CancerTreatment